Adalimumab (Humira®) (mAb-based) ELISA

ImmunoGuide® Enzyme immunoassay (ELISA) test kit for the determination of free Adalimumab (Humira®) in serum and plasma.<br><br>

The drug Adalimumab (trade name Humira®) is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor alpha (TNF-α). Adalimumab was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:ƙ constant regions. Adalimumab is produced by recombinant DNA technology in a mammalian cell expression system and it consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons. Adalimumab binds specifically to (TNF-α) and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Serum concentration of Adalimumab might be related to predict some clinical outcome during maintenance therapy. It was also possible that the surveillance of circulating Adalimumab concentration during maintenance therapy represents a direct and/or indirect factor for some other side effects. According to the data reported in the literature, Adalimumab given 40 mg subcutaneously every other week produces steady-state serum trough concentrations of 4 to 8 μg/mL, which are 3 to 7 times greater than the clinically effective serum concentrations (0.8–1.4 μg/mL).<br><br>

In this context, identification of biomarkers for (non-)response and risk factors for adverse drug reactions that might be related to serum concentrations and maintaining the effective concentration of Adalimumab in order to potentially avoid some side effects with a reliable method might be beneficial. For research use only, not for use in diagnostic procedures.